MedTrace Logo

CDK and Body Composition Study

NCT03697577 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-05-07

No results posted yet for this study

Summary

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

Conditions

Interventions

DIAGNOSTIC_TEST

CT scans

Patients will undergo CT or PETCT as part of standard of care

DIAGNOSTIC_TEST

DEXA scan

Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Jesus Anampa, MD · Montefiore Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-08
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697577 on ClinicalTrials.gov